The clinical intersection of depression and problematic cannabis use creates complex treatment challenges that affect millions globally, yet the precise scope of this comorbidity has remained unclear across different healthcare settings. Understanding these patterns could reshape how clinicians screen for dual diagnoses and approach integrated treatment protocols.
This comprehensive meta-analysis examined 55 studies encompassing over 3.2 million individuals to quantify the bidirectional relationship between major depressive disorder and cannabis use disorder. The analysis revealed striking disparities between clinical and community populations. Among individuals already receiving psychiatric care for depression, cannabis use disorder prevalence reached 28.45%, compared to just 4.61% in community samples. Conversely, depression rates among those with cannabis use disorders remained consistently elevated across both settings, affecting approximately one in five individuals regardless of whether they were in psychiatric treatment or community populations.
These findings illuminate a critical gap in current screening practices and treatment integration. The sixfold difference in cannabis use disorder prevalence between psychiatric and community depression populations suggests that traditional community-based studies may substantially underestimate the clinical burden. For practicing clinicians, this data argues for routine cannabis use screening in psychiatric settings, where the co-occurrence rate approaches 30%. The consistency of depression rates across cannabis use disorder populations also indicates that mood symptoms represent a core feature requiring attention in addiction treatment programs, rather than a secondary consideration. This represents confirmatory evidence with immediate clinical implications for dual-diagnosis protocols.